Type 2 Diabetes Management with CGM: Advanced Technologies & Treatments for Diabetes (ATTD) Conference

How can Continuous Glucose Monitoring (CGM) help people with type 2 diabetes feel more empowered and in control of their health? Exploring compelling new research presented at the Advanced Technologies & Treatments for Diabetes (ATTD) conference is host Cher Pastore, MS, RD, CDCES, BC-ADM, and guest Sim Singh, Senior Director of Behavioral and Translational Science at Dexcom. Together, they unpack findings from a 30-day study of Dexcom G7 use in people with type 2 diabetes, including those not on insulin. The results show significant improvements in glucose tracking, behavioral shifts like better nutrition and increased physical activity, and enhanced metabolic health and confidence - especially among CGM-naive users. Sim also shares insights from a Canadian trial and discusses how CGM is transforming diabetes education, not only for patients but for endocrinologists and primary care providers as well. Whether it’s supporting blood sugar monitoring, enabling personalized diabetes treatment, or simply helping people better understand their glucose patterns, this conversation highlights how CGM and biosensor technology are reshaping diabetes management - for people with type 1 diabetes, type 2 diabetes, and even prediabetes.